Greenwich LifeSciences, Inc.

As of June 18, 2025, Greenwich LifeSciences, Inc. is in a bearish trend with mixed signals from various indicators, including a bearish stance from Bollinger Bands and daily moving averages, despite some mild bullishness in the weekly MACD and KST.

As of March 2022, the management team of Greenwich LifeSciences, Inc. includes David McWilliams (Independent Chairman), Snehal Patel (CEO, CFO, Director), F. Joseph Daugherty (Chief Medical Officer, Director), Kenneth Hallock (Independent Director), and Eric Rothe (Independent Director). They oversee the company's strategic direction and operations.

Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company focused on developing GP2, an immunotherapy aimed at preventing breast cancer recurrence post-surgery. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $120.72 million.

As of Jun 18, Greenwich LifeSciences, Inc. has a market capitalization of 120.72 million and reported net sales of 0.00 million with a net profit of -16.58 million for the latest four quarters. As of Dec'24, shareholder's funds were 2.53 million and total assets were 4.09 million.